Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart plus chemotherapy/targeted therapy in advanced biliary tract cancer
ChiCTR2500108531Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of benmelstobart in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer (2 arms), sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoint: Progression-free survival. Started Sep 2025; status: recruiting.
02
Drugs
benmelstobart
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2500108531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108531.